Loading stock data…
$238.48-4.86 (-2.00%)
Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance in the United States.
Praxis Precision Medicines, Inc. in the Healthcare sector is trading at $238.48 with a market capitalization of $9.4B. Wall Street consensus targets $644.42 (19 analysts), implying a +170.2% move over the next 12 months. The stock is currently 39% below its 52-week high of $392.70, remaining 24.6% below its 200-day moving average. On fundamentals, Piotroski 3/9 flags weak fundamentals, Altman Z in the safe zone. Risk note: RSI 26 is oversold, raising the odds of a near-term bounce; MACD remains below its signal line. The Whystock Score of 75/100 reflects bullish alignment across trend, valuation and analyst targets.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0 | $0 | $0 | $0 | $0 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$96.90M↑ | -$105.86M↓ | -$97.04M↓ | -$78.36M↓ | -$76.07M |
| Net Income | -$83.72M↑ | -$92.56M↓ | -$88.91M↓ | -$73.93M↓ | -$71.13M |
Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance in the United States. The compa...